Background: Whether improvements in cardiometabolic health following weight loss (WL) are associated with changes in regional body fat distribution (gluteal vs. -android) is not well documented. Methods: Older (age: 70 ± 4 years; mean ± SD) adults with obesity were randomized to a 6-month WL program (WL; n = 47), accomplished using a hypocaloric, nutritionally complete, higher protein -(targeting ≥1.0 g/kg/day) meal plan, or a weight stability (WS; n = 49) program. Android, gynoid, visceral, and subcutaneous abdominal fat masses (via dual energy X-ray absorptiometry ) and fasting glucose and lipid profiles were assessed at baseline and 6 months. Results: The WL group lost more body weight (WL: –8.6% vs. WS: –1.7%, p < 0.01), resulting in a reduction in fat mass at each region only following WL (all p < 0.05). The decline in the ratio of android/gynoid fat mass also was significant only following WL, resulting in greater declines than WS (mean [95% CI]; WL: –0.026 [–0.040 to –0.011] vs. WS: 0.003 [–0.012 to 0.019] g, p < 0.01). The change in the ratio of visceral/subcutaneous abdominal fat mass was not significant in either group and did not differ between groups (WL: 0.65 [–0.38 to 1.68] vs. WS: 0.05 [–1.00 to 1.10] g, p = 0.42). In general, the improvements in glucose and lipid profiles were associated with declines in fat mass at the gynoid and android regions (r’s = 0.20–0.42, all p < 0.05), particularly the visceral depot but not the ratios. Conclusion: WL achieved via a hypocaloric, nutritionally complete, higher protein meal plan is effective in reducing body fat in the android, gynoid, and visceral depots, which relate to cardiometabolic improvements.

1.
Davis SR, Castelo-Branco C, Chedraui P, Lumsden MA, Nappi RE, Shah D, Villaseca P; Writing Group of the International Menopause Society for World Menopause Day 2012: Understanding weight gain at menopause. Climacteric 2012; 15: 419–429.
2.
Serra MC, Blumenthal JB, Addison OR, Miller AJ, Goldberg AP, Ryan AS: Effects of weight loss with and without exercise on regional body fat distribution in postmenopausal women. Ann Nutr Metab 2017; 70: 312–320.
3.
Beavers DP, Beavers KM, Lyles MF, Nicklas BJ: Cardiometabolic risk after weight loss and subsequent weight regain in overweight and obese postmenopausal women. J Gerontol A Biol Sci Med Sci 2013; 68: 691–698.
4.
Ryan AS, Nicklas BJ: Reductions in plasma cytokine levels with weight loss improve insulin sensitivity in overweight and obese postmenopausal women. Diabetes Care 2004; 27: 1699–1705.
5.
Tang M, Leidy HJ, Campbell WW: Regional, but not total, body composition changes in overweight and obese adults consuming a higher protein, energy-restricted diet are sex specific. Nutr Res 2013; 33: 629–635.
6.
Ryan AS, Ortmeyer HK, Sorkin JD: Exercise with calorie restriction improves insulin sensitivity and glycogen synthase activity in obese postmenopausal women with impaired glucose tolerance. Am J Physiol Endocrinol Metab 2012; 302:E145–E152.
7.
Rossi AP, Fantin F, Zamboni GA, Mazzali G, Zoico E, Bambace C, Antonioli A, Pozzi Mucelli R, Zamboni M: Effect of moderate weight loss on hepatic, pancreatic and visceral lipids in obese subjects. Nutr Diabetes 2012; 2:e32.
8.
Beavers KM, Nesbit BA, Kiel JR, Sheedy JL, Arterburn LM, Collins AE, Ford SA, Henderson RM, Coleman CD, Beavers DP: Effect of an energy-restricted, nutritionally complete, higher protein meal plan on body composition and mobility in older adults with obesity: a randomized controlled trial. J Gerontol A Biol Sci Med Sci 2018, Epub ahead of print.
9.
National Health and Nutrition Examination Survey: 2005–2006 Data Documentation, Codebook, and Frequencies, 2013.
10.
Ergun DL, Rothney MP, Oates MK, Xia Y, Wacker WK, Binkley NC: Visceral adipose tissue quantification using Lunar Prodigy. J Clin Densitom 2013; 16: 75–78.
11.
Beavers KM, Gordon MM, Easter L, Beavers DP, Hairston KG, Nicklas BJ, Vitolins MZ: Effect of protein source during weight loss on body composition, cardiometabolic risk and physical performance in abdominally obese, older adults: a pilot feeding study. J Nutr Health Aging 2015; 19: 87–95.
12.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–419.
13.
Okosun IS, Seale JP, Lyn R: Commingling effect of gynoid and android fat patterns on cardiometabolic dysregulation in normal weight American adults. Nutr Diabetes 2015; 5:e155.
14.
Lynch NA, Nicklas BJ, Berman DM, Dennis KE, Goldberg AP: Reductions in visceral fat during weight loss and walking are associated with improvements in VO(2 max). J Appl Physiol (1985) 2001; 90: 99–104.
15.
Phillips CL, Yee BJ, Trenell MI, Magnussen JS, Wang D, Banerjee D, Berend N, Grunstein RR: Changes in regional adiposity and cardio-metabolic function following a weight loss program with sibutramine in obese men with obstructive sleep apnea. J Clin Sleep Med 2009; 5: 416–421.
16.
Bjorntorp P, Bengtsson C, Blohme G, Jonsson A, Sjostrom L, Tibblin E, Tibblin G, Wilhelmsen L: Adipose tissue fat cell size and number in relation to metabolism in randomly selected middle-aged men and women. Metabolism 1971; 20: 927–935.
17.
Kissebah AH, Vydelingum N, Murray R, Evans DJ, Hartz AJ, Kalkhoff RK, Adams PW: Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab 1982; 54: 254–260.
18.
Singh P, Somers VK, Romero-Corral A, Sert-Kuniyoshi FH, Pusalavidyasagar S, Davison DE, Jensen MD: Effects of weight gain and weight loss on regional fat distribution. Am J Clin Nutr 2012; 96: 229–233.
19.
Bjorntorp P, Carlgren G, Isaksson B, Krotkiewski M, Larsson B, Sjostrom L: Effect of an energy-reduced dietary regimen in relation to adipose tissue cellularity in obese women. Am J Clin Nutr 1975; 28: 445–452.
20.
You T, Murphy KM, Lyles MF, Demons JL, Lenchik L, Nicklas BJ: Addition of aerobic exercise to dietary weight loss preferentially reduces abdominal adipocyte size. Int J Obes (Lond) 2006; 30: 1211–1216.
21.
Presta E, Leibel RL, Hirsch J: Regional changes in adrenergic receptor status during hypocaloric intake do not predict changes in adipocyte size or body shape. Metabolism 1990; 39: 307–315.
22.
You T, Berman DM, Ryan AS, Nicklas BJ: Effects of hypocaloric diet and exercise training on inflammation and adipocyte lipolysis in obese postmenopausal women. J Clin Endocrinol Metab 2004; 89: 1739–1746.
23.
Nicklas BJ, Rogus EM, Goldberg AP: Exercise blunts declines in lipolysis and fat oxidation after dietary-induced weight loss in obese older women. Am J Physiol 1997; 273:E149–E155.
24.
Waki H, Yamauchi T, Kadowaki T: [Regulation of differentiation and hypertrophy of adipocytes and adipokine network by PPARgamma]. Nihon Rinsho 2010; 68: 210–216.
25.
de Souza CJ, Eckhardt M, Gagen K, Dong M, Chen W, Laurent D, Burkey BF: Effects of pioglitazone on adipose tissue -remodeling within the setting of obesity and insulin resistance. Diabetes 2001; 50: 1863–1871.
26.
Garaulet M, Perez-Llamas F, Baraza JC, Garcia-Prieto MD, Fardy PS, Tebar FJ, Zamora S: Body fat distribution in pre-and post-menopausal women: metabolic and anthropometric variables. J Nutr Health Aging 2002; 6: 123–126.
27.
Aldrich ND, Reicks MM, Sibley SD, Redmon JB, Thomas W, Raatz SK: Varying protein source and quantity do not significantly improve weight loss, fat loss, or satiety in reduced energy diets among midlife adults. Nutr Res 2011; 31: 104–112.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.